Evidence map›Paper›PMID 29245914›Full record

ArticleOncotarget2017

Radiotherapy for stage IIA rectal cancer may not benefit all.

Xiang Hu, Ya-Qi Li, Qing-Guo Li, Yan-Lei Ma, Jun-Jie Peng, San-Jun Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiang HuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.
Ya-Qi LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.
Qing-Guo LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.
Yan-Lei MaDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.
Jun-Jie PengDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.
San-Jun CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study sought to determine whether additional radiotherapy is necessary in patients after optimal surgery for stage IIA rectal cancer and how the different covariates influence the efficacy of radiotherapy. The first primary rectal cancer was identified from the 1988-December 2013 Surveillance, Epidemiology and End Results database. We identified 13647 patients with IIA rectal cancer, in which 39.6% received neo-adjuvant radiotherapy and in another 14.96% patients the adjuvant radiotherapy were performed. Neo-adjuvant or adjuvant radiotherapy group had better survival with 10-Year cancer-specific survival estimates as 75.1% and 73.8% compared to 68.4% of no radiotherapy group (

Indexed as

outcomesradiotherapyrectal cancerstage IIA

Identifiers

PMID29245914
PMCPMC5725105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.